Compass Therapeutics Stock Short Ratio
| CMPX Stock | USD 1.50 0.01 0.67% |
Compass Therapeutics fundamentals help investors to digest information that contributes to Compass Therapeutics' financial success or failures. It also enables traders to predict the movement of Compass Stock. The fundamental analysis module provides a way to measure Compass Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Compass Therapeutics stock.
Compass | Short Ratio |
Compass Therapeutics Company Short Ratio Analysis
Compass Therapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Compass Therapeutics Short Ratio | 3.71 X |
Most of Compass Therapeutics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Compass Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Compass Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Compass Therapeutics is extremely important. It helps to project a fair market value of Compass Stock properly, considering its historical fundamentals such as Short Ratio. Since Compass Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Compass Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Compass Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Compass Therapeutics has a Short Ratio of 3.71 times. This is 4.87% lower than that of the Biotechnology sector and 49.93% lower than that of the Health Care industry. The short ratio for all United States stocks is 7.25% higher than that of the company.
Compass Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Compass Therapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Compass Therapeutics could also be used in its relative valuation, which is a method of valuing Compass Therapeutics by comparing valuation metrics of similar companies.Compass Therapeutics is currently under evaluation in short ratio category among its peers.
Compass Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Compass Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Compass Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Compass Therapeutics' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 2.3 M | State Street Corp | 2024-06-30 | 1.9 M | Tang Capital Management Llc | 2024-09-30 | 1.8 M | Baker Bros Advisors Lp | 2024-09-30 | 1.6 M | Northern Trust Corp | 2024-09-30 | 844.4 K | Monashee Investment Management Llc | 2024-09-30 | 500 K | Millennium Management Llc | 2024-06-30 | 433.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 335.8 K | Cm Management, Llc | 2024-09-30 | 310 K | Orbimed Advisors, Llc | 2024-06-30 | 22.4 M | Adage Capital Partners Gp Llc | 2024-06-30 | 11.1 M |
Compass Fundamentals
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (65.23) % | ||||
| Current Valuation | 76.48 M | ||||
| Shares Outstanding | 137.59 M | ||||
| Shares Owned By Insiders | 12.04 % | ||||
| Shares Owned By Institutions | 69.19 % | ||||
| Number Of Shares Shorted | 1.79 M | ||||
| Price To Book | 1.48 X | ||||
| Price To Sales | 241.19 X | ||||
| EBITDA | (48.47 M) | ||||
| Net Income | (42.49 M) | ||||
| Cash And Equivalents | 132.02 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 1.73 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.36 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (40.62 M) | ||||
| Short Ratio | 3.71 X | ||||
| Earnings Per Share | (0.35) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 32 | ||||
| Beta | 0.75 | ||||
| Market Capitalization | 205.01 M | ||||
| Total Asset | 156.88 M | ||||
| Retained Earnings | (315.31 M) | ||||
| Working Capital | 146.08 M | ||||
| Net Asset | 156.88 M |
About Compass Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Compass Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Compass Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Compass Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.